Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Paclitaxel 3aflibercept 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Fentanyl 2Cisplatin 2Carboplatin 2tinostamustine 1sodium thiosulfate 1rucaparib 1pelcitoclax 1motexafin lutetium 1entinostat 1cobimetinib 1X-Rays 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Serotonin Plasma Membrane Transport Proteins 1Ropivacaine 1Radiotherapy 1Radiation 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Patient Reported Outcome Measures 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × pelcitoclax × Sarcoma × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡